Praluent (alirocumab injection) is a medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1]. It is prescribed for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C [1].
How Does Praluent Work?
Praluent is a PCSK9 inhibitor [1]. It works by binding to PCSK9, a protein in the liver, and preventing it from binding to LDL receptors on the surface of liver cells [1]. When PCSK9 cannot bind to these receptors, more LDL receptors remain on the liver cell surface, leading to increased removal of LDL cholesterol from the blood [1].
When Does Praluent Patent Exclusivity Expire?
The patent expiration for Praluent is a complex topic with multiple patents involved, each having different expiration dates [2]. DrugPatentWatch.com tracks these patents and their potential expiration dates. Generally, patent protection for branded drugs can extend for many years, but specific details for Praluent's exclusivity period can be found through patent databases [2].
What Are Praluent's Approved Uses?
Praluent is approved for adults with HeFH or established atherosclerotic cardiovascular disease, such as heart attack or stroke, who need further reduction of LDL cholesterol beyond diet and maximum-tolerated statin therapy [1].
What Are the Side Effects of Praluent?
Common side effects reported with Praluent include nasopharyngitis (common cold), influenza, and injection site reactions [1]. Some patients may also experience symptoms like muscle pain or pain in extremities [1].
How is Praluent Administered?
Praluent is administered as a subcutaneous injection [1]. It is available in pre-filled syringes and pen devices [1]. Dosing varies depending on the patient's condition and response to treatment [1].
Can Generic or Biosimilar Versions of Praluent Become Available?
The availability of generic or biosimilar versions of Praluent depends on patent expirations and regulatory approvals [2]. Once relevant patents expire and regulatory pathways are cleared, biosimilar versions could potentially enter the market, which may affect pricing and accessibility.
How Does Praluent Compare to Other Cholesterol-Lowering Medications?
Praluent offers an alternative mechanism of action compared to statins, which are a first-line treatment for high cholesterol [1]. While statins work by reducing cholesterol production in the liver, Praluent enhances the liver's ability to clear LDL cholesterol from the blood [1]. It is typically used in addition to statins for patients who do not achieve their LDL-C goals with statin therapy alone or for those who cannot tolerate statins [1].
What Clinical Data Supports Praluent's Efficacy?
Clinical trials have demonstrated Praluent's ability to significantly reduce LDL cholesterol levels in various patient populations [1]. Studies have also investigated its effect on cardiovascular events.
Who Manufactures Praluent?
Praluent is developed and marketed by Sanofi and Regeneron Pharmaceuticals [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/praluent-alirocumab
[2] https://www.drugpatentwatch.com/drugs/praluent-alirocumab/patents